TiGenix secures Spanish reimbursement for ChondroCelect


The Spanish Health Authority has informed TiGenix that its cartilage repair therapy, ChondroCelect, will obtain national reimbursement in Spain. The company obtained national reimbursement in the Netherlands in 2012 and will continue working to obtain national reimbursement in other European countries later in 2013.

Currently, ChondroCelect is the first and the only cell therapy that has been granted market authorisation by the EU in accordance with the Advanced Therapy Medicinal Product regulation.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Spain, Spain, Spain, Spain

Related products in our Store...

Check out our most popular reports below or view more in our store